Skip to main content
. 2025 Aug 12;16:1625944. doi: 10.3389/fendo.2025.1625944

Figure 2.

A multi-part scientific figure displays various experimental results. Panel A shows a heatmap of lncRNA expression levels in two groups. Panels B and C present bar graphs of lncRNA expression with different conditions and treatments. Panel D features bar graphs showing expression levels of EHMT2 and LINC00657. Panel E contains bar graphs indicating mRNA expression levels of RUNX2, COL1A1, and BGLAP in different treatment groups. Panel F presents a Western blot analysis with bands for RUNX2, COL1A1, BGLAP, and GAPDH. Panel G shows an ALP activity assay with images and bar graph results. Panel H illustrates alizarin red staining with images and a bar graph showing absorbance measurements.

Overexpression of LINC00657 reversed the inhibitory role of EHMT2 on osteogenic differentiation. (A) Heatmap of 35 known significantly changed lncRNAs in T2DM-BMSCs. T: T2DM group, C: CON group. (B) qPCR detection of top 10 lncRNAs in T2DM group (vs CON group). (C) qPCR detection of six candidate lncRNAs after UNC0638 treatment (vs CON group). (D) T2DM-BMSCs were transfected with EHMT2 overexpression vector or co-transfected with LINC00657 overexpression vector, and qPCR was performed to detect expression levels of EHMT2 and LINC00657. (E–H) T2DM-BMSCs overexpressed with EHMT2 (and LINC00657) were induced for 7 days, osteogenic genes and proteins (RUNX2, COL1A1, and BGLAP) were detected using qPCR (E) and western blotting (F). ALP activity was detected using staining and activity quantification (G); mineralization level was detected using ARS staining following 14 days of induction (H). BMSCs, bone marrow-derived mesenchymal stem cells; T2DM, type 2 diabetes mellitus. *, P<0.05.